PMC7479234_01
The trend of white blood cell count, absolute peripheral blasts, and platelet and timelines of introduction of sorafenib for patient 1 (A) and patient 2 (B) are presented. Abbreviations: WBC, white blood cell, ABS BL, absolute blasts, PLT, platelets, S800 (sorafenib 800 mg daily), AZA 3 (azacitidine 75 mg/m2 Day 1-3 each cycle), AZA 5 (azacitidine 75 mg/m2 Day 1-3 each cycle), M, mutational profiling, S400 (sorafenib 400 mg daily).
fonc-10-01538-g0001.jpg
PMC7479234_02_fonc-10-01538-g0001.jpg
F1
Changes in blood counts with therapy are shown in Figure 1B.
(A-C) Updated trend of blast percentage, white blood count, and platelets from presentation in March 2015 to December 2019 with continuation of treatment with Vidaza + Sorafenib combination therapy for patient #1 are shown.
fonc-10-01538-g0002.jpg
PMC7479234_01_fonc-10-01538-g0002.jpg
F2
At the time of this report, the patient remains on sorafenib (200 mg PO BID continuous) and azacitidine (75 mg/m2 Days 1-3 every) therapy with the cycles repeated every 4-6 weeks based on count while maintaining MRD negative CR for over 60 months (see updated counts trend in Figures 2A-C).
PMC7479234_02
The trend of white blood cell count, absolute peripheral blasts, and platelet and timelines of introduction of sorafenib for patient 1 (A) and patient 2 (B) are presented. Abbreviations: WBC, white blood cell, ABS BL, absolute blasts, PLT, platelets, S800 (sorafenib 800 mg daily), AZA 3 (azacitidine 75 mg/m2 Day 1-3 each cycle), AZA 5 (azacitidine 75 mg/m2 Day 1-3 each cycle), M, mutational profiling, S400 (sorafenib 400 mg daily).
fonc-10-01538-g0001.jpg
PMC7479234_02_fonc-10-01538-g0001.jpg
F1
Changes in blood counts with therapy are shown in Figure 1B.